01
Injection
Administered under the skin according to your prescription.
Explore our care options. Online intake and Patient Portal access are not yet available.
Vitality & Performance
PT-141 (Bremelanotide)
Injectable · Physician evaluation
Understand the option
What is PT-141 (Bremelanotide)?
PT-141, also called bremelanotide, is an injectable peptide that activates melanocortin receptors, including receptors in the brain involved in sexual response.
How it works
From injection to signaling.
Follow the pathway from administration to receptor activity and sexual-response signaling.
02
Absorption
Bremelanotide is absorbed into the bloodstream.
03
Receptor activation
Activates melanocortin receptors. MC4 receptors are present in the brain and nervous system.
04
Sexual-response pathways
These pathways help the brain process sexual cues and coordinate sexual responses.
05
Individual response
Your physician reviews changes in desire, your experience, and side effects to guide ongoing care.
This illustrates drug actions and signaling pathways, not a guaranteed sequence of effects. Individual responses vary.
Understand the option
A closer look at PT-141.
Desire-focused
evaluation
A private discussion of changes in sexual interest and what those changes mean to you.
A different
mechanism
Works through melanocortin signaling involved in sexual response.
Care shaped
around you
Your medical history, current medications, and personal goals guide the evaluation.
Care built around you
What will your physician review?
Your physician considers the possible contributors to changes in desire and whether PT-141 is appropriate for you.
Your symptoms
Describe changes in sexual desire, how long they have been happening, and any concerns you want to discuss.
Your health picture
Share your blood-pressure and cardiovascular history, nausea or vomiting, and other medical conditions.
Your treatment plan
List all medications, including psychiatric medicines and opioids, and discuss pregnancy or breastfeeding.
Benefits, evidence & important considerations
FDA approval applies to Vyleesi for certain premenopausal women with acquired, generalized HSDD. It does not apply to compounded PT-141 or establish approval for use in men. Your physician explains any compounded or off-label care. Bremelanotide can increase blood pressure and cause nausea; cardiovascular history is important to review.
How do I get started?
Complete your secure PT-141 intake with your concerns, health history, and current medications. A licensed physician reviews your information and contacts you if more details are needed before deciding on care.
Patient education sources
A closer look at the brain study
In 31 premenopausal women with HSDD, researchers observed changes in regions linked to sexual imagery and self-monitoring. This does not establish treatment for performance anxiety or “brain rewiring.”
Read the human studyPrefer to ask a question first?
A free care coordinator call is available for general questions and is not required to begin intake.
Book an Optional Call →